Diffuse Large B-Cell Lymphoma News

News

FDA Grants Accelerated Approval to Glofitamab for Patients With R/R Diffuse Large B-Cell Lymphoma

06/23/2023

On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...

On June 15, 2023, the FDA...

06/23/2023

Oncology

News

FDA Grants Approval to Epcoritamab for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Grade Lymphoma

05/22/2023

Jordan Kadish ;

On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp for the treatment of relapsed/refractory DLBCL not otherwise specified, including DLBCL from indolent lymphoma and high-grade B-cell lymphoma.

On May 19, 2023, the FDA granted...

05/22/2023

Oncology

News

05/12/2023

Jordan Kadish ;

According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.

According to findings from a...

05/12/2023

Oncology

News

Potential Benefit of Bortezomib Plus R-CHOP Treatment for Patients With Activated B-Cell and Molecular High-Grade Subtype DLBCL

05/05/2023

Jordan Kadish ;

Findings from the phase 3 REMoDL-B trial indicate that patients with activated B-cell and molecular high-grade subtype diffuse large B-cell lymphoma may benefit from the addition of bortezomib to R-CHOP in initial therapy.

Findings from the phase 3...

05/05/2023

Oncology

News

FDA Grants Approval to Polatuzumab Vedotin for Patients With Previously Untreated DLBCL and High-Grade B-Cell Lymphoma

04/21/2023

Jordan Kadish ;

The FDA granted approval to polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) treatment for adult patients with previously untreated DLBCL, not otherwise specified, or high-grade B-cell...

The FDA granted approval to...

04/21/2023

Oncology

News

Subcutaneous Epcoritamab Combined With R-Dhax/C Yielded High ORR and CMR Rates in Patients With R/R DLBCL

02/10/2023

Jordan Kadish ;

An updated phase 1/2 dose escalation study found that a combination of subcutaneous epcoritamab and R-Dhax/C luxeptinib for patients with R/R diffuse b-cell lymphoma resulted in high ORR and CMR rates.

An updated phase 1/2 dose...

02/10/2023

Oncology

News

Bendamustine Demonstrates Safety, Efficacy for Lymphodepletion Before Tisagenlecleucel in R/R Large B-Cell Lymphoma

09/30/2022

Gina Tomaine ;

Bendamustine is an effective lymphodepletion regimen before tisagenlecleucel in patients with refractory/relapsed large B-cell lymphomas, according to a recent study.

Bendamustine is an effective...

09/30/2022

Oncology

News

PILOT Trial Supports Lisocabtagene Maraleucel as Second-Line Therapy for Relapsed/Refractory LBCL

09/02/2022

Gina Tomaine ;

Lisocabtagene maraleucel demonstrates promising safety and efficacy as a second-line treatment for patients with LBCL not eligible for hematopoietic stem-cell transplantation, according to findings from the PILOT trial.

Lisocabtagene maraleucel...

09/02/2022

Oncology

News

Targeted Therapy Combinations Feasible Before Chemoimmunotherapy for Newly Diagnosed DLBCL: Smart Start Trial

09/02/2022

Gina Tomaine ;

Rituximab plus lenalidomide and ibrutinib demonstrated significant clinical activity, manageable safety, and promising survival outcomes both alone and in combination with chemotherapy as a frontline treatment for newly diagnosed DLBCL in the...

Rituximab plus lenalidomide and...

09/02/2022

Oncology

News

Second-Line Lisocabtagene Maraleucel vs Standard of Care for Relapsed/Refractory LBCL: TRANSFORM Trial

08/23/2022

Gina Tomaine ;

An interim analysis of the phase 3 TRANSFORM trial has shown significantly improved EFS with second-line lisocabtagene maraleucel vs standard of care salvage immunochemotherapy followed by autologous stem cell transplantation in relapsed or...

An interim analysis of the phase...

08/23/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology